August 1, 2019

HEAL Partnership Committee Meeting - August 1, 2019

8:00 a.m.
Registration

8:30 a.m.
Welcome, Introductions, and Review of Agenda
Rebecca Baker, Ph.D., Director, HEAL Initiative, Office of the Director, National Institutes of Health (NIH)
Presentation

8:40 a.m.
HEAL Partnership Committee Update
Rebecca Baker, Ph.D., Director, HEAL Initiative, Office of the Director, NIH

9:00 a.m
NIH Programs for Developing and Testing Pain Treatments
Walter Koroshetz, M.D., Director, National Institute of Neurological Disorders and Stroke (NINDS) 
Presentation
Chris Austin, M.D., Director, National Center for Advancing Translational Sciences (NCATS) 
Presentation

9:20 a.m.
Industry Commentary on Animal Models
John Dunlop, Ph.D., Vice President, Neuroscience Research, Amgen
Chris Flores, M.D., Vice President, Glutamatergic Pathway Area Leader, Janssen R&D

9:35 a.m.
Industry Commentary on Human Based Screening Platforms
John Dunlop, Ph.D., Vice President, Neuroscience Research, Amgen
Chris Flores, M.D., Vice President, Glutamatergic Pathway Area Leader, Janssen R&D

9:50 a.m.
Break

10:10 a.m.
Preclinical Screening Platforms – Animal Models 
Preclinical Screening Platform for Pain 
Smriti Iyengar, Ph.D., Program Director, NINDS 
Presentation

Summary of 2019 Animal Pain Models 
Michael Oshinsky, Ph.D., Program Director, NINDS
Presentation

10:50 a.m.
Animal Models Discussion
Group Discussion

11:35 a.m.
Lunch

12:20 p.m.
Human-Based Screening Platforms
Christine Colvis, Ph.D., Director, Drug Development Partnership Programs, NCATS
Presentation
Chris Austin, M.D., Director, NCATS

12:50 p.m.
Human Based Screening Discussion
Group Discussion

1:35 p.m.
EPPIC-Net Update
Barbara Karp, M.D., Program Director, NINDS
Presentation 

2:05 p.m.
Summary of the Day’s Discussion and Next Steps
Rebecca Baker, Ph.D., Director, HEAL Initiative, Office of the Director, NIH
David Wholley, Senior Vice President, Research Partnerships, Foundation for the NIH

2:20 p.m.
Considerations of Additional Ideas for HPC
Group Discussion

2:40 p.m.
Final Remarks and Closing
Francis Collins, M.D., Ph.D., Director, NIH